CR20140553A - Compuestos de fenoxietil piperidina - Google Patents

Compuestos de fenoxietil piperidina

Info

Publication number
CR20140553A
CR20140553A CR20140553A CR20140553A CR20140553A CR 20140553 A CR20140553 A CR 20140553A CR 20140553 A CR20140553 A CR 20140553A CR 20140553 A CR20140553 A CR 20140553A CR 20140553 A CR20140553 A CR 20140553A
Authority
CR
Costa Rica
Prior art keywords
compounds
piperidine
phenoxietil
intermediates
synthesis
Prior art date
Application number
CR20140553A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20140553A publication Critical patent/CR20140553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20140553A 2012-06-29 2014-12-03 Compuestos de fenoxietil piperidina CR20140553A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
CR20140553A true CR20140553A (es) 2015-02-04

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140553A CR20140553A (es) 2012-06-29 2014-12-03 Compuestos de fenoxietil piperidina

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
HUE035698T2 (en) * 2013-12-17 2018-05-28 Lilly Co Eli Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102861190B1 (ko) * 2019-01-22 2025-09-17 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
CA2536870C (en) * 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
AU2005238291A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
KR20070006890A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドールアミド誘導体
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
ES2518919T3 (es) 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CA2789665C (en) 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
WO2012039972A1 (en) * 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
EP2729141B1 (en) * 2011-07-04 2015-12-09 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor agonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
DOP2014000287A (es) 2015-01-31
AU2013280875A1 (en) 2014-12-04
AP2014008164A0 (en) 2014-12-31
KR101653476B1 (ko) 2016-09-01
ZA201408632B (en) 2017-06-28
HRP20171515T1 (hr) 2017-11-17
JO3296B1 (ar) 2018-09-16
SG11201408641UA (en) 2015-01-29
NZ701933A (en) 2017-01-27
PH12015500009B1 (en) 2020-10-09
ME02840B (me) 2018-01-20
PT2867207T (pt) 2017-11-01
PE20150182A1 (es) 2015-02-13
US8962659B2 (en) 2015-02-24
UA114325C2 (uk) 2017-05-25
HUE034425T2 (en) 2018-02-28
BR112014031616A2 (pt) 2017-06-27
RS56452B1 (sr) 2018-01-31
US9402838B2 (en) 2016-08-02
US20140005226A1 (en) 2014-01-02
AR091429A1 (es) 2015-02-04
GT201400288A (es) 2015-08-27
DK2867207T3 (en) 2017-09-11
PH12015500009A1 (en) 2015-03-02
IL236219A (en) 2017-12-31
HK1203937A1 (en) 2015-11-06
TWI599561B (zh) 2017-09-21
MX2014015953A (es) 2015-07-17
PL2867207T3 (pl) 2018-01-31
AU2013280875B2 (en) 2015-09-24
JP2015522018A (ja) 2015-08-03
CL2014003535A1 (es) 2015-05-08
MX345324B (es) 2017-01-25
CN104411684B (zh) 2016-08-24
CO7151507A2 (es) 2014-12-29
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
MA37686A1 (fr) 2016-09-30
TN2014000501A1 (en) 2016-03-30
BR112014031616B1 (pt) 2022-06-21
WO2014004229A1 (en) 2014-01-03
EA024392B1 (ru) 2016-09-30
ES2644812T3 (es) 2017-11-30
MY173878A (en) 2020-02-26
EA201492255A1 (ru) 2015-03-31
SI2867207T1 (sl) 2017-10-30
JP6127136B2 (ja) 2017-05-10
IL236219A0 (en) 2015-02-01
CA2875569C (en) 2016-04-19
EP2867207B1 (en) 2017-08-09
CA2875569A1 (en) 2014-01-03
CY1119425T1 (el) 2018-03-07
US20150126555A1 (en) 2015-05-07
MA37686B1 (fr) 2017-04-28
KR20150013893A (ko) 2015-02-05
TW201412717A (zh) 2014-04-01
LT2867207T (lt) 2017-10-10
EP2867207A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
CR20140554A (es) Compuestos de acido dimetil-benzoico
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CR20150370A (es) Compuestos antivirales
UY33735A (es) Compuestos antivirales
CR20150045A (es) Inhibidores de hepatitis c
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2019003738A (es) Compuestos antivirales.
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
CU20150021A7 (es) Piridinonas bicíclicas novedosas
GT201400288A (es) "compuestos de fenoxietil piperidina"
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
GT201400242A (es) "nuevos compuestos de pirazol"
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
UY35746A (es) Derivados de fenilalanina sustituidos
GT201200216A (es) Nuevos derivados terciarios de 8-hidroxiquinolina-7carboxamida y usos de los mismos.